Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer

Annals of Oncology

Volumn 13, Issue 12, 2002, Pages 1862-1867

  Lorusso, V ^a   Crucitta, E ^a   Panza, N ^b   Silvestris, N ^a   Guida, M ^a   Carpagnano, F ^c   Mancarella, S ^a   Sambiasi, D ^a   De Lena, M ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b Caldarelli Hospital   (Italy)

^c Ospedale San Paolo di Bari   (Italy)

Author keywords

Chemotherapy; Gemcitabine; Non small cell lung cancer; Paclitaxel; Vinorelbine

Indexed keywords

CARBOPLATIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; VINBLASTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036924416     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf308     Document Type: Article

References (22)

1. Haskell CM. Chemotherapy and survival in patients with non-small cell lung cancer. A contrary view. Chest 1991; 99: 1325-1326.
2. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866-1872.
3. Soquet PJ, Chauvin F, Boissel JP et al. Polichemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.
4. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
5. Cullen MH, Billingham LJ, Woodroffe CM et al. Mytomicin, ifosfamide, and cisplatin, in unresectable non-small cell lung cancer: effects on survival and quality. J Clin Oncol 1999; 17: 3188-3194.
6. Ellis PA, Smith IE, Hardy JR et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 1995; 71: 366-370.
7. Cellerino R, Tummarello D, Piga A. Chemotherapy or not in advanced non-small cell lung cancer? Lung Cancer 1990; 6: 99-109.
8. Bakker W, van Oosterom AT, Aaronson NK et al. Vindesine cisplatin and bleomycin combination chemotherapy in non-small cell lung cancer: survival and quality of life. Eur J Cancer Clin Oncol 1986; 22: 963-970.
9. Giaccone G. New drugs for the management of lung cancer. Br J Hosp Med 1996; 55: 634-638.
10. Lorusso V, Carpagnano F, Frasci G et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 2000; 18: 405-411.
11. Chen YM, Perng RP, Yang KY et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer. Chest 2000; 117: 1583-1589.
12. Krajnik G, Mohn-Staudner A, Thaler J et al. Vinorelbine-gemcitabine in advanced non-small cell lung cancer (NSCLC): an AASLC phase II trial. Ann Oncol 2000; 11: 993-998.
13. Laack E, Mende T, Benk J et al. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer, a phase II trial. Eur J Cancer 2001; 37: 583-590.
14. Iaffaioli RV, Facchini G, Tortoriello A et al. Phase I study of vinorelbine and paclitaxel in small cell lung cancer. Cancer Chemother Pharmacol 1997; 41: 86-90.
15. Douillard JY, Lerouge D, Monnier A et al. Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. Br J Cancer 2001; 84: 1179-1184.
16. Kosmidis P. Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non small cell lung cancer. Oncology 2000; 7 (Suppl 4): 41-48.
17. Masters G, Mauer A, Hoffman PH et al. A phase I/II study of paclitaxel ifosfamide and vinorelbine, with G-CSF support in advanced non-small-cell lung cancer. Ann Oncol 1998; 9: 677-680.
18. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization 1979.
19. Simon R. Confidence interval for reporting results of clinical trials. Ann Intern Med 1986; 105: 429-435.
20. The American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15: 2996-3018.
21. Isla D, Rosell R, Sanchez JJ et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2001; 19: 1071-1077.
22. Frasci G, Panza N, Comella P et al. Cisplatin, gemcitabine and paclitaxel in locally advanced or metastatic non-small cell lung cancer: a phase I-II study. J Clin Oncol 1999; 17: 2316-2325.